Skip to Content
Merck
All Photos(1)

Documents

S-021

Supelco

Sertraline hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H18Cl3N
CAS Number:
79559-97-0
Molecular Weight:
342.69
EC Number:
200-659-6
MDL number:
MFCD00895772
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Cl.CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c3ccccc13

InChI

1S/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/m0./s1

InChI key

BLFQGGGGFNSJKA-XHXSRVRCSA-N

Gene Information

human ... SLC6A4(6532)

Related Categories

General description

Sertraline, marketed as the brand drug Zoloft®, is an SSRI antidepressant used in the treatment of major depression as well as obsessive-compulsive, panic, and social anxiety disorders. This Certified Snap-N-Spike® Solution is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Application


  • Environmental impact assessment: Sertraline hydrochloride is analyzed for its environmental effects, particularly focusing on its metabolites and their reactive properties. This research is critical for assessing the potential ecological risks associated with pharmaceuticals (Jin et al., 2024).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zoloft is a registered trademark of Pfizer, Inc.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 1 - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Kaddurah-Daouk et al.
Translational psychiatry, 3, e223-e223 (2013-01-24)
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline or placebo in a double-blind 4-week
Population pharmacokinetic modeling of sertraline treatment in patients with Alzheimer disease: the DIADS-2 study.
Claire H Li et al.
Journal of clinical pharmacology, 53(2), 234-239 (2013-02-26)
Yvette I Sheline et al.
The American journal of psychiatry, 169(11), 1185-1193 (2013-03-28)
In order to assess the effect of gray matter volumes and cortical thickness on antidepressant treatment response in late-life depression, the authors examined the relationship between brain regions identified a priori and Montgomery-Åsberg Depression Rating Scale (MADRS) scores over the
Jay H Shore
The American journal of psychiatry, 170(3), 256-262 (2013-03-02)
The provision of psychiatric treatment via live interactive videoconferencing, frequently termed telepsychiatry, is a viable option for psychiatrists to provide care to individual patients, populations, and communities faced with limited access and to move the point of care delivery into
Andre R Brunoni et al.
JAMA psychiatry, 70(4), 383-391 (2013-02-08)
Transcranial direct current stimulation (tDCS) trials for major depressive disorder (MDD) have shown positive but mixed results. To assess the combined safety and efficacy of tDCS vs a common pharmacological treatment (sertraline hydrochloride, 50 mg/d). Double-blind, controlled trial. Participants were
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service